US FDA approves Scholar Rock's muscle weakness drug
11/09/2026 22:24
US FDA approves Scholar Rock's muscle weakness drug Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday approved Scholar Rock's SRRK.O therapy to treat a rare genetic condition that causes muscle weakness.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova